Abstract
Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions such as inflammation. Since ten years now, it is well known that this enzyme exists under two forms: a constitutive (COX-1) and an inducible form (COX-2). Both enzymes are sensitive to inhibition by conventional nonsteroidal antiinflammatory drugs (NSAIDs). Observations that COX-1, involved in several homeostatic processes, played a housekeeping role while COX-2 expression was associated with inflammation and other pathologies such as cancer proliferation have led to the development of COX-2 selective inhibitors in order to reduce the classical side-effects, of which gastric irritation is the most common, associated with the use of conventional NSAIDs.
Current Medicinal Chemistry
Title: Recent Advances in Inducible Cyclooxygenase (COX-2) Inhibition.
Volume: 7 Issue: 11
Author(s): Xavier de Leval, Jacques Delarge, Fabian Somers, Pascal de Tullio, Yves Henrotin, Bernard Pirotte and Jean-Michel Dogne
Affiliation:
Abstract: Cyclooxygenase is the key enzyme in the biosynthesis of prostanoids, biologically active substances that are involved in several physiological processes but also in pathological conditions such as inflammation. Since ten years now, it is well known that this enzyme exists under two forms: a constitutive (COX-1) and an inducible form (COX-2). Both enzymes are sensitive to inhibition by conventional nonsteroidal antiinflammatory drugs (NSAIDs). Observations that COX-1, involved in several homeostatic processes, played a housekeeping role while COX-2 expression was associated with inflammation and other pathologies such as cancer proliferation have led to the development of COX-2 selective inhibitors in order to reduce the classical side-effects, of which gastric irritation is the most common, associated with the use of conventional NSAIDs.
Export Options
About this article
Cite this article as:
de Leval Xavier, Delarge Jacques, Somers Fabian, de Tullio Pascal, Henrotin Yves, Pirotte Bernard and Dogne Jean-Michel, Recent Advances in Inducible Cyclooxygenase (COX-2) Inhibition., Current Medicinal Chemistry 2000; 7 (11) . https://dx.doi.org/10.2174/0929867310007011041
DOI https://dx.doi.org/10.2174/0929867310007011041 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Protein Tyrosine Phosphatase Detection Using Chemical Probes
Anti-Cancer Agents in Medicinal Chemistry Exploring Mechanisms of MicroRNA Downregulation in Cancer
MicroRNA ACE Inhibitors and ARBs for Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Significant Induction of Soluble TNFR2 Compared with TNFR1 in Serum Samples of HIV Patients with or without Antiretroviral Medication
Infectious Disorders - Drug Targets Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer’s Disease
Current Alzheimer Research Statistical Optimization of Pharmacogenomics Association Studies: Key Considerations from Study Design to Analysis
Current Pharmacogenomics and Personalized Medicine Adipobiology of Disease: Adipokines and Adipokine-Targeted Pharmacology
Current Pharmaceutical Design Pharmacogenetics of the Metabolic Disturbances and Atherosclerosis Associated with Antiretroviral Therapy in HIV-Infected Patients
Current Pharmaceutical Design Meet Our Editorial Board Member:
Current Alzheimer Research The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Chemokines as Drug Targets in Type 1 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Susceptibility Genes for the Side Effect of Antipsychotics on Body Weight and Obesity
Current Drug Targets Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Treatment of MDR1 Mutant Dogs with Macrocyclic Lactones
Current Pharmaceutical Biotechnology Preconditioning by Oxygen-Glucose Deprivation Preserves Cell Proliferation and Reduces Cytotoxicity in Primary Astrocyte Cultures
CNS & Neurological Disorders - Drug Targets Role of Metals in Neuronal Apoptosis: Challenges Associated with Neurodegeneration
Current Alzheimer Research Non-Cardiomyocytes in Heart Regeneration
Current Drug Targets Piper sarmentosum Roxb. Root Extracts Confer Neuroprotection by Attenuating Beta Amyloid-Induced Pro-Inflammatory Cytokines Released from Microglial Cells
Current Alzheimer Research